Sign Up to like & get
recommendations!
1
Published in 2020 at "Prescriber"
DOI: 10.1002/psb.1873
Abstract: Rybelsus (semaglutide) is the first GLP‐1 agonist for the treatment of type 2 diabetes to be available as an oral formulation. This article discusses its properties, efficacy and adverse effects.
read more here.
Keywords:
rybelsus oral;
agonist semaglutide;
formulation glp;
glp agonist ... See more keywords